German China

USA: Automated Biotherapeutic Characterization Collaboration to Ensure Efficient Workflows for Biopharmaceutical Characterization

Editor: MA Alexander Stark

A collaboration between Waters and Genovis aims at developing and marketing complete routine biopharmaceutical characterization workflows based on the Waters Bio Accord LC-MS System, Andrew+ pipetting robot and Genovis' Smart Enzymes.

Related Company

The collaboration between Genovis and Waters is among others based on the Bio Accord system.
The collaboration between Genovis and Waters is among others based on the Bio Accord system.
(Bild: Waters)

Milford/USA — The goal of the collaboration between Waters and Genovis is to develop automated workflows for the rapid and consistent characterization of critical quality attributes (CQAs) of monoclonal antibodies (mAbs) and other protein-based drugs in bioprocess development, formulation, stability testing and quality control (QC). The workflows in development are based on the pairing of the Waters Bio Accord LC-MS System, Andrew+ pipetting robot and Genovis Smart Enzymes and will focus on addressing the application needs of GxP laboratories in the following areas.

One issue that is to be solved by the collaboration is the bottleneck created by up-front sample preparation. This is largely due to the number of manual steps involved and the outmoded technology by which samples are readied for analysis. By combining Genovis’ Smart Enzymes with automation, liquid chromatography/time-of-flight mass spectrometry and application-specific software workflows from Waters, the companies intend to increase productivity of biotherapeutic analysis.

The enzymatic workflows that we will be jointly developed are to help customers in their efforts to bring safe and novel therapeutics to patients, faster.

(ID:47364996)